Author

Carson Veldstra

Observed names: C Veldstra, C. Veldstra, Carson A. Veldstra

Institution: Inhibrx (United States)

Observed institution: Inhibrx (United States)

ORCID: 0009-0001-2809-0234

Observed ORCID: 0009-0001-2809-0234

OpenAlex ID: A5038102558

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2023 · Vivek Subbiah, Sant P. Chawla, et al. · Clinical Cancer Research · 58

Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study

2024 · Mark L. Brantly, Brooks T. Kuhn, et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 17

Recombinant Human Alpha-1 Antitrypsin (AAT) Protein INBRX-101 Demonstrates Potential to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT Deficiency

2023 · B.T. Kuhn, A. Veale, et al. · American Journal of Respiratory and Critical Care Medicine · 2

Recombinant AAT-Fc fusion protein INBRX-101 achieves normal serum AAT levels in patients with alpha-1 antitrypsin deficiency (AATD)

2022 · A Veale, H Farah, et al. · European Respiratory Journal · 2

Protease Inhibitory Specificity Profile of the Recombinant Human Alpha-1 Antitrypsin (AAT)-Fc Fusion Protein INBRX-101

2024 · J. Zour, L. Nguyen, et al. · American Journal of Respiratory and Critical Care Medicine · 1

Delineating a reference interval for functional alpha-1 antitrypsin in the serum of healthy Pi*MM donors using an anti-neutrophil elastase capacity assay

2026 · Keith David Merdek, Dobrin Draganov, et al. · Respiratory Research

B78-14 Establishing a Reference Interval for Functional Alpha-1 Antitrypsin in the Serum of Healthy Pi*MM Donors Using an Anti-neutrophil Elastase Capacity Assay

2026 · K D Merdek, D Draganov, et al. · American Journal of Respiratory and Critical Care Medicine

Supplementary Data 1 from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2025 · Vivek Subbiah, Sant P. Chawla, et al.

Supplementary Data 1 from Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2024 · Vivek Subbiah, Sant P. Chawla, et al.

Data from Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2024 · Vivek Subbiah, Sant P. Chawla, et al.

Supplementary Data 1 from Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2024 · Vivek Subbiah, Sant P. Chawla, et al.

Late Breaking Abstract - Validation of assays measuring functional alpha-1 antitrypsin (AAT) in patients with AAT deficiency (AATD)

2023 · Jason Zour, Varun Ramani, et al. · European Respiratory Journal

Supplementary Data 1 from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2023 · Vivek Subbiah, Sant P. Chawla, et al.

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2023 · Vivek Subbiah, Sant P. Chawla, et al.

Supplementary Data 1 from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

2023 · Vivek Subbiah, Sant P. Chawla, et al.

Works count: 15

Citation count: 80

H-index: 2

I10-index: 2